enGene (ENGN) announced that the FDA has selected detalimogene voraplasmid to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene to Present at Piper Sandler Healthcare Conference
- enGene Holdings Closes $130 Million Public Offering
- enGene 12.559M share Spot Secondary priced at $8.50
- enGene Holdings Prices $130 Million Public Offering to Advance Genetic Medicine Programs
- enGene Holdings Announces Public Offering of Common Shares